Kenvue Inc. (NYSE:KVUE) Position Trimmed by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 9.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 169,937 shares of the company’s stock after selling 17,800 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Kenvue were worth $3,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Grove Bank & Trust lifted its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $23.03 on Friday. The company’s fifty day moving average is $23.03 and its two-hundred day moving average is $22.43. The firm has a market capitalization of $44.19 billion, a price-to-earnings ratio of 43.45, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.56%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Barclays reduced their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, April 14th. Citigroup increased their target price on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.